Apollomics Net Income From Continuing Ops Over Time
| APLM Stock | 18.30 0.38 2.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Apollomics Performance and Apollomics Correlation. Apollomics | Build AI portfolio with Apollomics Stock |
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Apollomics Class A and related stocks such as SeaStar Medical Holding, Moleculin Biotech, and Athira Pharma Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
| MBRX | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (3.9 M) | (9.8 M) | (11.9 M) | (13.2 M) | (17.4 M) | (15.9 M) | (29 M) | (26.3 M) | (21.8 M) | (19.6 M) | (20.6 M) |
| LNAI | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (113.4 M) | (39.7 M) | (88.4 M) | (178 M) | (160.2 M) | (168.2 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| BLRX | (17 M) | (17 M) | (17 M) | (17 M) | (11.1 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| GOVX | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (3 M) | (18.6 M) | (14 M) | (23.8 M) | (25 M) | (22.5 M) | (21.4 M) |
| ANL | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (56.7 M) | (58.8 M) | (104.9 M) | (51.9 M) | (46.7 M) | (49 M) |
Apollomics Class A and related stocks such as SeaStar Medical Holding, Moleculin Biotech, and Athira Pharma Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Apollomics Class A | APLM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 989 East Hillsdale |
| Exchange | NASDAQ Exchange |
null 18.3
Check out Apollomics Performance and Apollomics Correlation. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Apollomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.